Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Almatis is a global leader in the development, manufacture, and supply of premium specialty alumina and alumina-based products. Formerly the specialty chemicals division of Alcoa, the company provides high-purity alumina for critical applications in refractories, technical ceramics, and polishing. In the healthcare and life sciences sectors, Almatis is a key supplier of high-purity alumina used in medical ceramics for hip and dental implants, as well as pharmaceutical-grade aluminum hydroxide used as an antacid and vaccine adjuvant. Owned by the Turkish group OYAK since 2015, Almatis operates a global network of production facilities and research centers across Europe, North America, and Asia. Its products are essential for the manufacturing of high-performance medical devices and pharmaceutical formulations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Almatis.